Acucela Inc. is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting tens of millions of individuals worldwide. Since its founding in 2002, the Company has enjoyed strong financial health via its investors and strategic partnerships.
The Company is developing orally-delivered visual cycle modulation (VCM) therapies that selectively target cells within the retina to protect visual acuity. These compounds have the potential to treat blinding eye diseases, including the dry form of age-related macular degeneration (AMD), that affect tens of millions of people around the world.
Modulating the visual cycle has been shown to protect the retina from light damage, to improve retinal vasculature and to reduce the accumulation of retinal-related toxic by-products such as A2E, which is implicated in AMD.
In preclinical and clinical studies, Acucela’s novel proprietary VCM compounds demonstrated the ability to slow the visual cycle in multiple blinding eye diseases including dry AMD, retinopathy of prematurity, Stargardt disease and diabetic retinopathy.
Age-related macular degeneration (AMD) occurs in "dry" and "wet" forms. AMD is a leading cause of blindness in the United States, and is estimated to affect more than 10 million Americans and 120 million people worldwide. Dry AMD is the most common form, representing approximately 90% of all cases.
(Reference: The Retinal Pharmaceuticals Market Report, Market Scope, 2012)
In early 2013, Acucela initiated a 2-year phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration. Acucela launched its Phase 2 clinical trial, evaluating the investigational oral treatment ACU-4429, in patients with dry age-related macular degeneration (dry AMD) in January 2010. The trial builds upon the promising preclinical findings and data from Acucela’s Phase 1 clinical studies. These Phase 1 data have been presented at key scientific meetings and provide support and clinical rationale for Acucela’s ACU-4429 clinical development program in patients with dry AMD. In March 2010, Acucela received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429 for the treatment of dry AMD.
Acucela's VCM compounds have a good safety profile: they are non-retinoid and can be administered orally, unlike current therapeutics for many eye diseases, which must be injected into the eye.
Although our primary focus is on developing safe and effective treatments for AMD, we also have programs underway to create next-generation therapeutics for other potentially devastating ophthalmic diseases, including glaucoma, Stargardt disease, retinopathy of prematurity, and diabetic retinopathy.
Acucela was founded in 2002 by eminent ophthalmologist Ryo Kubota, M.D., Ph.D., the discoverer of the gene that causes glaucoma. The company is based in Seattle, Washington. Please find below the company's Vision and Mission.
Innovative ophthalmology company focused on developing therapies to treat sight threatening diseases.
- To address unmet medical needs in sight threatening diseases through scientific innovations.
- To build a unique company with continuous value creation for society.
- To create an excellent working environment and quality of life for employees.